Caira Surgical is innovating radar technology to make it precise enough for use in navigating surgeons through knee-replacement procedures, where every millimeter matters for an accurate outcome, co-founders Jon Greenwald and Mort Meftah explain to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Greenwald and Meftah sit down with BI analyst Matt Henriksson for an in-depth interview about Caira, how sub-millimeter radar technology can be an improvement over traditional optical tracking for orthopedic surgery and the potential path to expand navigation and robotic capabilities within ambulatory surgical centers.

Caira Surgical is innovating radar technology to make it precise enough for use in navigating surgeons through knee-replacement procedures, where every millimeter matters for an accurate outcome, co-founders Jon Greenwald and Mort Meftah explain to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Greenwald and Meftah sit down with BI analyst Matt Henriksson for an in-depth interview about Caira, how sub-millimeter radar technology can be an improvement over traditional optical tracking for orthopedic surgery and the potential path to expand navigation and robotic capabilities within ambulatory surgical centers.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Caira’s New Vision for Knee Surgery

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ba6c2f83-7f5a-4ff7-ae6b-b10200edae93/transcript

“In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,” says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire’s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women’s health, the evolving AI landscape and the personal values — integrity, work ethic and mission — that shape how she invests and leads.

&ldquo;In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,&rdquo; says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire&rsquo;s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women&rsquo;s health, the evolving AI landscape and the personal values &mdash; integrity, work ethic and mission &mdash; that shape how she invests and leads.

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/11341ee2-b121-40cd-858d-b41200952d3e/transcript

“Nothing excites me as much as the potential for AI,” Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&D leader, explains why today’s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient stratification can transform target selection, drug creation and trials. Tessier-Lavigne also details why Xaira is chasing “high-hanging fruit,” the hard-to-drug targets others can’t reach, and what it will take to reverse Eroom’s Law.

&ldquo;Nothing excites me as much as the potential for AI,&rdquo; Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&amp;D leader, explains why today&rsquo;s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient stratification can transform target selection, drug creation and trials. Tessier-Lavigne also details why Xaira is chasing &ldquo;high-hanging fruit,&rdquo; the hard-to-drug targets others can&rsquo;t reach, and what it will take to reverse Eroom&rsquo;s Law.

Xaira’s War on Trial-and-Error Drug Development

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e37a2db7-b788-4227-92c6-b40a00fd1db4/transcript

“IVL in general is an enabler for physicians to do very complex procedures — it’s simple, it’s easy to use and it’s safe. So even a physician that doesn’t have a lot of experience doing complex cases can now treat patients that they previously weren’t treating,” AVS Pulse Chairman Mark Toland tells Bloomberg Intelligence, referring to calcified arterial lesions in peripheral artery disease. In this Vanguards of Health Care episode, Toland joins BI analyst Matt Henriksson to discuss how the Pulse intravascular lithotripsy (IVL) system is differentiated vs. current technology, aiming to make treatment more flexible. He also highlights clinical results from the POWER PAD II pivotal trial, the commercial strategy ahead of FDA approval, and the expanding opportunity as aging demographics drive more hardened lesions that require IVL.

&ldquo;IVL in general is an enabler for physicians to do very complex procedures &mdash; it&rsquo;s simple, it&rsquo;s easy to use and it&rsquo;s safe. So even a physician that doesn&rsquo;t have a lot of experience doing complex cases can now treat patients that they previously weren&rsquo;t treating,&rdquo; AVS Pulse Chairman Mark Toland tells Bloomberg Intelligence, referring to calcified arterial lesions in peripheral artery disease. In this Vanguards of Health Care episode, Toland joins BI analyst Matt Henriksson to discuss how the Pulse intravascular lithotripsy (IVL) system is differentiated vs. current technology, aiming to make treatment more flexible. He also highlights clinical results from the POWER PAD II pivotal trial, the commercial strategy ahead of FDA approval, and the expanding opportunity as aging demographics drive more hardened lesions that require IVL.

AVS’ Toland on Next Lithotripsy Launch

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/91509729-b58e-4a94-aacc-b40400e06835/transcript

Caira’s New Vision for Knee Surgery

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips